CARDIOQUIN
Pre-Launchquinidine polygalacturonate
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIOQUIN (quinidine polygalacturonate) is an oral tablet formulation of quinidine, a Class IA antiarrhythmic agent used to treat cardiac arrhythmias. The polygalacturonate salt formulation provides modified-release characteristics compared to standard quinidine salts. This product is currently in pre-launch phase as a New Drug Application (NDA).
Pre-Launch
Pre-launch stage indicates early commercial infrastructure build with smaller team, focused on launch readiness and regulatory navigation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CARDIOQUIN at pre-launch offers early-stage product team exposure with opportunities to shape commercial strategy, medical positioning, and launch execution. Career growth depends on successful regulatory approval and market entry timing.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.